ompD Antibody

What is OmpD and why is it significant in bacterial immunology?

OmpD (Outer Membrane Protein D) is a trimeric porin protein predominantly found in the outer membrane of Salmonella species, particularly Salmonella Typhimurium (STm). It serves as a channel that permits the passive diffusion of small molecules across the bacterial outer membrane. OmpD has significant immunological importance because:

• It is a key target for protective antibody responses against nontyphoidal Salmonella infections

• Anti-OmpD antibodies can substantially reduce bacterial burdens in the liver, spleen, and blood after infection with both laboratory and clinical strains of Salmonella

• Unlike some bacterial surface antigens, OmpD generates sufficient exposure through the lipopolysaccharide (LPS) layer to permit antibody binding and subsequent bacterial clearance

• Its expression is regulated by environmental conditions like anaerobiosis and pH, suggesting a role in bacterial adaptation

OmpD's immunological significance was established in multiple studies showing that immunization with purified OmpD can elicit protective antibody responses that moderate Salmonella infection independently of responses to other bacterial components like LPS or flagellin (FliC) .

How does OmpD structure contribute to its recognition by antibodies?

OmpD forms a trimeric structure in the bacterial outer membrane, creating a distinct footprint or "tunnel" through the surrounding LPS O-antigen (O-Ag) layer. This structural arrangement has several implications for antibody recognition:

• Atomistic molecular dynamics simulations indicate that OmpD trimers generate footprints within the O-Ag layer that are sufficiently sized for a single IgG Fab fragment to access the protein's surface-exposed epitopes

• The trimeric arrangement positions critical epitopes on the outer loops of the protein, particularly loops 5, 6, and 8, which extend beyond the membrane core

• The most accessible epitope appears to be located on loop 6, which contains the A263 residue in STm OmpD (or S263 in S. Enteritidis OmpD)

• Some antibodies specifically recognize only the trimeric form of OmpD but not the monomeric form, suggesting that the quaternary structure creates unique conformational epitopes

This trimeric structure is crucial for OmpD's immunogenicity, as it enables partial exposure of protein epitopes despite the surrounding O-Ag, which would otherwise shield most monomeric proteins from antibody access.

How do OmpD antibodies differ from antibodies to other outer membrane proteins?

OmpD antibodies show distinct characteristics that differentiate them from antibodies targeting other outer membrane proteins:

Unlike antibodies to the monomeric OmpA protein, antibodies to the trimeric OmpD are highly protective because the trimeric structure creates sufficient space in the O-Ag layer for antibody binding. Studies have shown that "antibodies to monomeric OmpA are not protective" as they cannot effectively penetrate the O-Ag barrier to reach their target .

What are the recommended methods for purifying OmpD for antibody production?

The purification of OmpD for antibody production requires specialized techniques to maintain its native structure while achieving high purity. Based on research protocols, the following methodology is recommended:

• Bacterial strain selection: Use Salmonella Typhimurium strains with mutations in other major porins (e.g., SH7454 with ompC::Tn10) to simplify purification and reduce contamination with similar porins

• Extraction procedure:

  • Grow bacteria under appropriate conditions (often anaerobic to enhance OmpD expression)

  • Isolate outer membrane fraction using differential centrifugation

  • Extract membrane proteins using detergents (typically 2% SDS)

  • Perform size exclusion chromatography to separate OmpD trimers

• Verification of purity:

  • SDS-PAGE analysis under both heat-denatured and non-heat-denatured conditions

  • Western blotting with known anti-OmpD antibodies

  • Mass spectrometry analysis

  • Endotoxin testing (should be ≤2 endotoxin units per 10μg of protein)

• Critical considerations:

  • Use O-Ag-deficient strains to ensure antibodies are truly specific to OmpD and not contaminating LPS

  • Verify that purified OmpD maintains its trimeric structure, as some antibodies only recognize the native trimeric form

  • Consider using cyanogen bromide (CNBr) digestion followed by peptide separation for epitope mapping studies

When preparing OmpD for immunization, researchers must ensure minimal LPS contamination to avoid generating antibodies to O-Ag rather than OmpD itself. Studies have validated specificity by immunizing with OmpD purified from triple-mutant strains lacking OmpF, OmpC, and O-Ag .

What assays are most effective for evaluating anti-OmpD antibody functionality?

Multiple complementary assays should be employed to comprehensively evaluate anti-OmpD antibody functionality:

• Binding assays:

  • ELISA using purified OmpD as coating antigen

  • Flow cytometry to measure antibody binding to intact bacteria

  • Western blotting against denatured and non-denatured OmpD preparations

• Functional assays:

  • Serum bactericidal assay (SBA): Measures complement-dependent killing mediated by anti-OmpD antibodies using human serum depleted of anti-Salmonella antibodies as a complement source

  • Opsonophagocytosis assay: Evaluates phagocytic uptake of bacteria opsonized with anti-OmpD antibodies

  • In vivo protection studies: Challenge immunized mice with virulent Salmonella strains and measure bacterial burdens in liver, spleen, and blood

• Epitope mapping:

  • Peptide arrays covering the OmpD sequence

  • Competition assays using monoclonal antibodies to defined epitopes

  • Testing binding to OmpD mutants with alterations in specific surface loops

• Cross-reactivity assessment:

  • Binding to OmpD from different Salmonella serovars

  • Binding to OmpD in the presence or absence of O-Ag

  • Binding to chimeric strains with swapped O-Ag types

Research has demonstrated that anti-STmOmpD antibodies can promote >100-fold reduction in bacterial numbers when bacteria are opsonized prior to infection, and can enhance complement-dependent killing in SBAs . The combination of these assays provides a comprehensive evaluation of both binding capacity and functional activity of anti-OmpD antibodies.

How can researchers accurately quantify the protective efficacy of OmpD antibodies?

Quantifying the protective efficacy of OmpD antibodies requires a multi-faceted approach combining in vitro and in vivo methods:

• In vivo challenge models:

  • Intraperitoneal challenge: Measure bacterial burdens in liver, spleen, and blood 24 hours post-infection

  • Studies show ≥100-fold median reduction in liver and spleen bacterial burdens and ~10,000-fold reduction in blood following immunization with STmOmpD

  • Oral challenge models to mimic natural infection route

  • Passive transfer of anti-OmpD antibodies followed by challenge to isolate antibody effects

• Correlation analyses:

  • Correlate antibody titers with bacterial reduction in tissues

  • Compare protective efficacy between different immunization protocols

  • Analyze isotype-specific contributions to protection

• Comparative strain studies:

  • Challenge with homologous vs. heterologous Salmonella strains

  • Use of chimeric strains expressing alternative OmpD variants or O-Ag types

  • Testing against clinical isolates (e.g., invasive African strain D23580)

• Statistical analysis:

  • Calculate fold-reduction in bacterial burdens compared to control groups

  • Determine minimum protective antibody titers

  • Analyze correlations between in vitro binding/functional assays and in vivo protection

Research has shown that mice immunized with STmOmpD and challenged with STm D23580 (an invasive African isolate) exhibited a ≥100-fold median reduction in bacterial burdens in liver and spleen, and a near-10,000-fold reduction in blood bacterial numbers compared to control mice . Similar levels of protection were observed against the laboratory strain SL1344, confirming the robust protective capacity of anti-OmpD antibodies.

How do single amino acid changes in OmpD affect antibody binding and protection?

Single amino acid substitutions in OmpD can dramatically impact antibody binding and protective efficacy, highlighting the fine specificity of the antibody response. Research has revealed:

• The OmpD proteins from S. Typhimurium (STm) and S. Enteritidis (SEn) differ by only a single amino acid substitution (A263S), yet antibodies raised against STmOmpD show significantly reduced binding and protection against SEn

• This critical A263S variation is located in loop 6 on the outer rim of the OmpD trimer, at the position most distal from the hydrophobic core of the membrane and potentially most accessible to antibodies

• Molecular dynamics simulations indicate that this position is located at the interface between OmpD and the surrounding LPS O-Ag, making it particularly sensitive to both protein sequence and O-Ag structure

• When O-Ag is removed from SEn, binding of anti-STmOmpD antibodies increases dramatically, suggesting that additional conserved epitopes become accessible in the absence of the O-Ag barrier

What is the relationship between O-antigen structure and OmpD antibody accessibility?

The O-antigen (O-Ag) component of LPS plays a critical role in regulating antibody access to OmpD epitopes, through both physical and chemical interactions:

• Physical barrier effects:

  • O-Ag forms a dense layer surrounding the bacterial surface that restricts antibody access

  • OmpD trimers generate "tunnels" or footprints in this O-Ag layer that allow limited antibody access

  • Molecular dynamics simulations indicate these tunnels are sized to accommodate at most a single Fab fragment

• Chemical structure influence:

  • Different O-Ag types (e.g., O4 in STm vs. O9 in SEn) interact differently with OmpD loops

  • STm (O4) and SEn (O9) O-Ag differ in their use of acetylabequose and tyvelose sugars, respectively

  • Chimeric strains with swapped O-Ag types (STm expressing O9 and SEn expressing O4) show reduced binding of anti-STmOmpD antibodies compared to wild-type STm

• Combined effects:

  • The specific pairing of OmpD sequence and its native O-Ag type appears critical for optimal antibody recognition

  • Loss of O-Ag (O-Ag-deficient mutants) dramatically increases binding of anti-STmOmpD antibodies to both STm and SEn, revealing additional conserved epitopes

  • Studies with chimeric strains show that matched native O-Ag and OmpD are needed for optimal protection

This intricate relationship between protein epitopes and O-Ag structure represents a sophisticated bacterial strategy to enhance antigenic diversity while limiting fitness costs, as minor changes in either component can significantly alter antibody recognition.

What explains the variable cross-protection of OmpD antibodies between Salmonella serovars?

The limited cross-protection of OmpD antibodies between Salmonella serovars results from multiple interacting factors:

• Sequence variation in immunodominant epitopes:

  • Even single amino acid changes (like A263S between STm and SEn) in surface-exposed loops can dramatically reduce antibody binding

  • There is a strong correlation between specific amino acid polymorphisms and O-Ag usage by different Salmonella serogroups

• O-Ag structure constraints:

  • Different O-Ag types create distinct physical and chemical environments around OmpD

  • The specific pairing of OmpD variant with its native O-Ag appears optimized for certain epitope presentations

  • Chimeric studies show that swapping O-Ag types reduces antibody binding and protection

• Epitope accessibility hierarchy:

  • A limited number of variable epitopes (including the one containing A263) appear most accessible in the presence of O-Ag

  • More conserved epitopes are often occluded by O-Ag and only become accessible when O-Ag is absent

  • Evidence suggests "most IgG that binds OmpD on O-Ag-expressing bacteria targets a limited number of variable proteinaceous epitopes that include A263S, whereas O-Ag occludes binding to the larger number of epitopes conserved between the two proteins"

• Evolutionary implications:

  • This system represents a form of "combinatorial antigenic diversity" that maximizes serovar-specific immune evasion while minimizing the genetic changes required

How do different antibody isotypes vary in their ability to target OmpD?

Antibody isotype significantly influences the capacity to bind OmpD and mediate protection, with distinct mechanisms of action:

• IgG subclass effects:

  • Not all IgG isotypes provide equivalent protection against Salmonella

  • This correlates with differential access to OmpD epitopes in the presence of O-Ag

  • Higher affinity IgG subclasses may better penetrate the physical barrier posed by the O-Ag layer

  • Fc receptor engagement differs between subclasses, affecting downstream effector functions

• Mechanism-based differences:

  • Cell-dependent killing: Some anti-OmpD antibodies operate primarily through opsonophagocytosis

  • Complement-dependent killing: Other anti-OmpD antibodies primarily activate complement cascades

  • Studies have identified that "IgG antibodies to the porin protein OmpD can offer cell-dependent or complement-dependent protection"

• Experimental observations:

  • Anti-OmpD antibodies can enhance complement-dependent killing, as demonstrated in serum bactericidal assays

  • Opsonization with anti-OmpD antibodies can reduce bacterial numbers post-infection

  • The binding profile of different antibody isotypes to intact bacteria versus purified OmpD shows distinctive patterns

• Structure-based constraints:

  • The physical dimensions of the antibody isotype (particularly the Fab region) relative to the OmpD "tunnel" through the O-Ag layer is crucial

  • Molecular dynamics simulations confirm that "at most a single Fab fragment could be accommodated within the footprint of the tunnel at a time"

Understanding these isotype-specific effects is vital for rational vaccine design and for interpreting the protective mechanisms of anti-OmpD antibody responses.

What molecular dynamics approaches can best model OmpD-antibody interactions in the bacterial envelope?

Advanced molecular dynamics (MD) simulations have proven invaluable for understanding the complex OmpD-antibody interactions within the bacterial envelope context:

• Comprehensive membrane system modeling:

  • Construction of atomistic models incorporating OmpD trimers embedded in realistic outer membrane lipid compositions

  • Inclusion of full LPS molecules with core and O-Ag components at physiological densities

  • Integration of multiple OmpD trimers to capture potential cooperative effects

  • Typical simulation systems contain >1 million atoms for realistic representation

• Analysis of OmpD exposure and accessibility:

  • Calculation of OmpD "footprint" size within the O-Ag layer

  • Quantification of tunnel dimensions that permit antibody access

  • Measurement of exposure frequency and duration for specific epitope regions

  • Analysis of dynamic interactions between OmpD loops and surrounding O-Ag sugars

• Antibody binding simulations:

  • Steered molecular dynamics to model antibody approach and binding

  • Extended simulations (>70 nanoseconds) to capture complete binding events

  • Assessment of physical constraints that limit binding of complete IgG versus Fab fragments

  • Energy calculations to quantify binding stability in the presence of O-Ag

• Comparative studies across serovars:

  • Parallel simulations of OmpD from different serovars in their native O-Ag environments

  • Analysis of interactions between loops 5, 6, and 8 with different O-Ag structures

  • Investigation of how single amino acid substitutions alter the protein-O-Ag interface

These sophisticated MD approaches have revealed that "OmpD trimers generate footprints within the O-Ag layer sufficiently sized for a single IgG Fab to access" and that "steered MD simulation of full IgG binding demonstrated that it can overcome the steric hindrance of the O-Ag layer to reach the OmpD loops" , providing crucial mechanistic insights into antibody accessibility.

How can epitope mapping techniques be optimized for OmpD antibody research?

Effective epitope mapping for OmpD antibodies requires specialized approaches to account for its trimeric structure and complex interaction with LPS:

• Structural biology approaches:

  • X-ray crystallography of OmpD-Fab complexes

  • Cryo-electron microscopy of OmpD trimers with bound antibody fragments

  • Hydrogen-deuterium exchange mass spectrometry to identify protected regions upon antibody binding

  • Nuclear magnetic resonance (NMR) studies of isolated OmpD loops

• Biochemical mapping strategies:

  • Chemical cross-linking coupled with mass spectrometry

  • Limited proteolysis in the presence/absence of antibodies

  • Cyanogen bromide (CNBr) digestion and separation of peptide fragments by SDS-PAGE, as used in early OmpD studies

  • Screening of peptide fragments with monoclonal antibodies by Western blotting

• Genetic and immunological methods:

  • Site-directed mutagenesis of surface-exposed loops

  • Creation of chimeric proteins swapping loops between OmpD from different serovars

  • Competition assays between monoclonal antibodies targeting different epitopes

  • Phage display with random peptide libraries to identify mimotopes

• Combined computational-experimental approaches:

  • In silico epitope prediction based on molecular dynamics simulations

  • Validation of predicted epitopes through targeted mutagenesis

  • Correlation of antibody binding profiles with protection in immunization-challenge studies

  • Construction of epitope accessibility maps incorporating O-Ag structure data

Research has shown that epitopes on loop 6, particularly around residue A263 in STm (S263 in SEn), are immunodominant in the presence of O-Ag, while additional conserved epitopes become accessible only in O-Ag-deficient bacteria . Comprehensive epitope mapping using these optimized techniques can guide rational vaccine design targeting the most protective and accessible OmpD epitopes.

What strategies can enhance cross-protection of OmpD-based vaccines across Salmonella serovars?

Developing broadly protective OmpD-based vaccines requires innovative approaches to overcome serovar-specific limitations:

• Multi-epitope vaccine design:

  • Identification and incorporation of conserved, protective epitopes from multiple OmpD variants

  • Creation of chimeric OmpD proteins combining key protective epitopes from different serovars

  • Focus on epitopes that remain accessible despite O-Ag variability

  • Potential modification of surface loops to increase antibody accessibility

• O-Ag interaction engineering:

  • Modification of OmpD surface loops to reduce O-Ag-mediated epitope masking

  • Co-administration with enzymes that partially degrade O-Ag to increase epitope exposure

  • Development of adjuvants that temporarily modify outer membrane organization

• Alternative immunization strategies:

  • Prime-boost protocols using OmpD from different serovars

  • Co-immunization with multiple OmpD variants to broaden antibody repertoire

  • Use of live attenuated vectors with engineered OmpD expression

  • DNA or RNA vaccine approaches encoding modified OmpD sequences

• Adjuvant optimization:

  • Selection of adjuvants that promote broad epitope recognition

  • Formulations that enhance B cell receptor crosslinking for better responses to less accessible epitopes

  • TLR agonists that promote antibody affinity maturation for stronger binding

Research has established that "anti-STmOmpD antibodies can reduce bacterial burdens in the liver, spleen, and blood after infection with laboratory and clinical strains of STm" , but improving cross-protection remains challenging due to the intricate relationship between OmpD sequence and O-Ag structure. Future vaccine strategies must account for both protein sequence variation and the impact of O-Ag on epitope accessibility.

How can structural biology approaches advance our understanding of OmpD antibody interactions?

Advanced structural biology techniques offer powerful tools to dissect the complex interactions between antibodies and OmpD:

• High-resolution structure determination:

  • X-ray crystallography of OmpD trimers in complex with protective antibody fragments

  • Cryo-electron microscopy (cryo-EM) of intact OmpD-antibody complexes

  • Single-particle cryo-EM of OmpD embedded in membrane nanodiscs with bound antibodies

  • Solid-state NMR studies of OmpD in native-like membrane environments

• Dynamics and conformational analyses:

  • Hydrogen-deuterium exchange mass spectrometry to map antibody binding footprints

  • Solution NMR studies of isolated OmpD loops to characterize flexibility and antibody interactions

  • In situ fluorescence studies using labeled antibodies to track binding dynamics

  • Single-molecule FRET to monitor conformational changes upon antibody binding

• Integrated membrane system studies:

  • Cryo-electron tomography of OmpD in outer membrane vesicles with bound antibodies

  • Neutron reflectometry to analyze antibody penetration into O-Ag layers

  • Surface plasmon resonance with reconstituted membrane systems

  • Atomic force microscopy to visualize OmpD distribution and antibody binding on bacterial surfaces

• Translation to vaccine design:

  • Structure-based redesign of OmpD loops to enhance antibody accessibility

  • Identification of minimal protective epitopes for peptide vaccine development

  • Computational optimization of OmpD-based immunogens based on structural constraints

  • Rational design of antibody-inducing conformational epitopes

These approaches would build upon existing knowledge, such as the identification that "OmpD is a trimeric porin with homology to OmpF and OmpC" and that "for OmpD many antibodies only recognize the protein in trimeric but not monomeric form" , to develop a comprehensive structural understanding of protective epitopes and antibody accessibility within the complex bacterial surface environment.

What are the implications of OmpD-antibody research for understanding bacterial immune evasion mechanisms?

Research on OmpD antibody interactions reveals sophisticated bacterial immune evasion strategies with broad implications:

This research reveals that bacteria employ sophisticated structural adaptations to limit antibody efficacy while maintaining protein function, with "both the chemical and physical structure of O-Ag being key for the presentation of specific epitopes within proteinaceous surface-antigens" . These insights have profound implications for understanding bacterial evolution and developing more effective vaccines against diverse Gram-negative pathogens.

What are the critical quality control parameters for OmpD antibody validation?

Rigorous quality control is essential for validating anti-OmpD antibodies in research applications:

• Specificity validation:

  • Western blot analysis against wild-type bacteria and OmpD-deficient mutants

  • Testing against OmpD from different Salmonella serovars to determine cross-reactivity

  • Evaluation of binding to other porins (OmpC, OmpF) to confirm absence of cross-reactivity

  • Studies have confirmed "a lack of cross-reactivity between surface binding mAb to these 3 porins"

• Structural recognition assessment:

  • Comparative binding analysis to native trimeric versus denatured monomeric OmpD

  • Many antibodies "only recognize the protein in trimeric but not monomeric form"

  • Confirmation of recognition of specific OmpD epitopes through peptide mapping

  • Testing against OmpD point mutants to confirm epitope specificity

• Functional validation:

  • Bactericidal activity in serum bactericidal assays using human complement

  • Opsonophagocytic activity using appropriate phagocytic cells

  • In vivo protection studies in mouse models of infection

  • Research confirms anti-STmOmpD antibodies can "enhance complement-dependent killing"

• Technical validation parameters:

  • Determination of affinity constants for purified OmpD

  • Epitope mapping using peptide arrays or hydrogen-deuterium exchange

  • Validation of binding in different buffer conditions and in the presence of potential interferents

  • Lot-to-lot consistency testing for polyclonal antibodies

These validation steps are critical because antibody efficacy is highly dependent on epitope specificity, with research showing that even single amino acid changes (like A263S) can dramatically affect binding and protection . Comprehensive validation ensures reliable and reproducible results in OmpD research applications.

How do experimental conditions affect the analysis of OmpD-antibody interactions?

Experimental conditions significantly influence the detection and characterization of OmpD-antibody interactions:

• Buffer composition effects:

  • Ionic strength can alter antibody-antigen binding kinetics

  • Detergent concentration and type affects OmpD conformational stability

  • pH can influence both antibody binding and OmpD loop conformation

  • Divalent cation concentration may affect OmpD structure and LPS interactions

• Sample preparation considerations:

  • Heat denaturation converts OmpD trimers to monomers, affecting recognition by conformation-specific antibodies

  • OmpD extraction methods influence retention of native structure

  • LPS co-purification can interfere with antibody binding studies

  • Research shows "for OmpD many antibodies only recognize the protein in trimeric but not monomeric form"

• LPS and O-Ag variables:

  • Testing with intact bacteria versus purified protein yields different binding profiles

  • O-Ag-deficient versus O-Ag-sufficient bacteria show dramatically different antibody accessibility

  • "Binding of anti-STmOmpD IgG to O-Ag-deficient SEn was comparable with STm" despite poor binding to O-Ag-sufficient SEn

  • Use of live versus fixed bacteria may affect O-Ag layer organization

• Methodological variations:

  • Direct binding versus competition assays provide complementary information

  • Antibody concentration ranges must be carefully calibrated

  • Flow cytometry versus ELISA may detect different populations of binding antibodies

  • Temperature affects both antibody binding kinetics and OmpD conformational dynamics

Researchers must carefully control these variables to obtain reliable and reproducible data, as "the pairing of OmpD with its native O-Ag being essential for optimal protection after immunization" demonstrates the critical interplay between experimental conditions and biological reality.

What are the most informative animal models for evaluating OmpD antibody protection?

Selecting appropriate animal models is crucial for evaluating the protective efficacy of anti-OmpD antibodies:

• Mouse models of systemic infection:

  • Intraperitoneal challenge model:

    • Allows assessment of bacterial burden in liver, spleen, and blood

    • Studies show "≥100-fold median reduction in bacterial burdens in the liver and spleen, and a near-10,000-fold reduction in the median bacterial numbers in the blood"

    • Provides quantitative measure of antibody protection

    • Suitable for comparing protection against different Salmonella strains

• Specialized mouse models:

  • Passive transfer models:

    • Transfer of anti-OmpD serum to naïve mice before challenge

    • Allows isolation of antibody effects from cellular immunity

    • Studies show "bacteria were opsonized with complement-inactivated anti-STmOmpD or control sera prior to infection"

  • Knockout mouse models:

    • Fc receptor-deficient mice to assess antibody effector functions

    • Complement-deficient mice to evaluate complement-dependent effects

    • Mice lacking specific immune cell populations

• Ex vivo functional assays:

  • Serum bactericidal assays:

    • Uses human sera depleted of anti-STm antibodies as complement source

    • "Anti-STmOmpD antibodies enhanced complement-dependent killing, whereas sera from control mice did not"

  • Opsonophagocytic killing assays:

    • Measures phagocyte-mediated killing of opsonized bacteria

    • Can identify cell types involved in antibody-mediated protection

• Translation-relevant models:

  • Natural infection route models:

    • Oral challenge to mimic natural infection

    • Evaluation of protection in intestinal tissue and systemic sites

  • Models with human-relevant features:

    • Humanized mouse models expressing human Fc receptors

    • Models incorporating human microbiota

    • Age-appropriate models relevant to at-risk populations

When evaluating antibody protection, it's important to compare multiple Salmonella strains, including laboratory strains (like SL1344), clinically relevant isolates (like D23580), and strains with genetic modifications (O-Ag deficient, chimeric O-Ag expressing) . This comprehensive approach provides robust assessment of antibody protective efficacy and mechanisms.